Pediatric Oncology Group of Ontario
Prevention and treatment of anticipatory chemotherapy-induced nausea and vomiting in pediatric cancer patients and hematopoietic stem cell recipients: Clinical practice guideline update
Abstract
This 2021 clinical practice guideline update provides recommendations for preventing anticipatory chemotherapy-induced nausea and vomiting (CINV) in pediatric patients. Recommendations are based on systematic reviews that identified (1) if a history of acute or delayed CINV is a risk factor for anticipatory CINV, and (2) interventions for anticipatory CINV prevention and treatment. A strong recommendation to optimize acute and delayed CINV control in order to prevent anticipatory CINV is made. Conditional recommendations are made for hypnosis, systematic desensitization, relaxation techniques, and lorazepam for the secondary prevention of anticipatory CINV. No recommendation for the treatment of anticipatory CINV can be made.
Source and rights
Published by Pediatric blood & cancer, 2021. The guideline itself is at the source linked here.
Prognia summarises this guideline for reference and education. It is not medical advice. Always check the official guideline and current local protocols before acting on it.
At a glance
- Organisation
- Pediatric Oncology Group of Ontario
- Published
- 2021
- Applies to
- 🇨🇦 Canada
- Scope
- National
- Journal
- Pediatric blood & cancer
- PubMed
- 33686754
More in oncology
- Non-Small Cell Lung Cancer, Version 4.2026, NCCN Clinical Practice Guidelines In OncologyNational Comprehensive Cancer Network · 2026
- Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for the Systemic Treatment of Patients with HER2+ Breast Cancer in Both the Early and Metastatic Settings (2025 Update)Research Excellence, Active Leadership Canadian Breast Cancer Alliance (REAL Alliance) [2] · 2026
